Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 13, 2001

View Archived Issues

Licensing opportunity from NIH: defensin-tumor antigen fusions

Licensing opportunity from NIH: viral chemokine-antigen fusion proteins

MorphoSys reaches milestone in HuCAL collaboration with Bayer

Demegen to acquire Periodontix; Periodontix pipeline described

OGS reports progress of Vevesca in clinical trials for Gaucher's disease

Primate studies demonstrate utility of anti-HIV antibody combination as passive immunotherapy

Cancer vaccine designed at Progenics induces antitumor immune response in clinical trial

Sanofi Synthelabo/Organon pentasaccharide can be reversed only by Neutralase

Genzyme Transgenics updates rhATIII development status

Use of pregabalin restricted in certain clinical trial patients

TSP-1 antiangiogenic gene therapy and its application in prostate cancer

Starlix launched in U.S. for type 2 diabetes

First-line therapy with rituximab in follicular lymphoma with low tumor burden

Increased survival results with Aphton's antigastrin vaccine reported

GenVec to apply PEDF technology to the treatment of blindness

Small study provides preliminary evidence for efficacy of modafinil in ADHD

Arriva to develop ilomastat as respiratory disease treatment

Anti-TNF-alpha antisense strategy proves beneficial in rat model of ICH

Avigen/Bayer hemophilia B collaboration becomes effective

SkyePharma to manufacture NK-104 for Kowa

Advance in treatment, diagnosis of prion diseases patented by Canadian researchers

New agents for AIDS from Merck and Tularik interact with HIV integrase

Antifungal sordarin derivative discovered at Fujisawa

Nonsedating anxiolytic agents reported by Egis

Spectrum of new peptide antibiotic encompasses both Gram-positive and Gram-negative pathogens

Antiangiogenic tyrosine kinase inhibitors disclosed by Celltech scientists in recent patent

Adenosine derivatives from CV Therapeutics useful in treatment, diagnosis of CAD

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...